News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Mark T. Fleming, MD

Articles by Mark T. Fleming, MD

Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

Episode 14: Multidisciplinary Care Insights Across World GU 2025

ByManojkumar Bupathi, MD, MS,Benjamin Garmezy, MD,Mehmet Asim Bilen, MD,Sid Sadler,Kerry R. Schaffer, MD,Mark T. Fleming, MD,Jeff Yorio, MD,Mike Lattanzi, MD,Elizabeth Kessler, MD,Benjamin L. Maughan, MD, PharmD,Alan Tan, MD

September 18th 2025

Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

ByManojkumar Bupathi, MD, MS,Benjamin Garmezy, MD,David Morris, MD, MS,Tanya B. Dorff, MD,Mark T. Fleming, MD

March 5th 2025

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

2 experts are featured in this series.

Episode 2: Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

ByManojkumar Bupathi, MD, MS,Ben Garmezy, MD,David Morris, MD, MS,Tanya B. Dorff, MD,Mark T. Fleming, MD

March 5th 2025

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

Mark T. Fleming, MD, Talks Use of 18F-rhPSMA-7.3 for PET/CT in Recurrent Prostate Cancer

ByMark T. Fleming, MD

May 19th 2022

Mark T. Fleming, MD, spoke about how use of 18F-rhPSMA-7.3 for PET/CT scans in patients with recurrent prostate cancer bests conventional imaging.

Latest Updated Articles

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
March 5th 2025
Episode 2: Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
March 5th 2025
Episode 14: Multidisciplinary Care Insights Across World GU 2025
September 18th 2025

Trending on CancerNetwork

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Cevostamab May Fill Gap in Multiple Myeloma Armamentarium

ASCO Updates 340B Policy Statement to Expand Access, Improve Transparency

Learning to Implement Novel Cellular Therapies in Hematologic Oncology Care

131 Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)